Target intelligence / Profile preview

Spinster homolog 1 (SPNS1)

Target
SPNS1
Molecular classification
Transporter, Major facilitator superfamily (MFS), Solute carrier family 63 (SLC63)
01

Overview

Spinster homolog 1 (SPNS1) is a lysosomal membrane transporter belonging to the solute carrier family 63 (SLC63) and the major facilitator superfamily (MFS) that mediates the efflux of lysophospholipids—especially lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE)—from the lysosomal lumen to the cytosol[1][2][3][4]. This transport is essential for recycling lysolipids into phosphatidylcholine for membrane synthesis and cellular homeostasis, notably via the Lands cycle. SPNS1 activity is driven by a proton gradient and involves key residues required for substrate binding and proton sensing, critical for its transporter mechanism[1][2]. Loss‐of‐function mutations can cause lysosomal lipid accumulation, autophagic defects, and have been associated with neurodevelopmental disorders and pathologies resembling lysosomal storage diseases in animal models and humans[1][4]. SPNS1 displays selectivity for zwitterionic lysophospholipids (LPC, LPE), but does not transport anionic lysophospholipids or sphingolipids such as sphingosine-1-phosphate[3]. As of 2024, SPNS1 is not directly targeted by approved drugs, but its role in cellular metabolism suggests potential as a future therapeutic target in diseases with autophagic or lipid storage components.

Other names
Protein spinster homolog 1SPNS1SPIN1PP20300HSpin1nrsSPINLLATSLC63A1SLC62A1solute carrier family 63 member 1sphingolipid transporter 1 (putative)spinster-like protein 1
02

Biological functions

Lysophospholipid transport (notably lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylglycerol (LPG))Maintenance of lysosomal and cellular lipid homeostasisSupport of phosphatidylcholine metabolism and recyclingSupport of autophagy and autophagosome formationPotential intracellular signaling via lysolipids
03

Disease associations

Lysosomal storage disease phenotypesNeurodevelopmental disorders (including severe neurodevelopmental symptoms in humans with specific SPNS1 mutations)Metabolic disorders (due to disrupted phospholipid homeostasis and autophagy)
04

Safety considerations

Potential safety issues relate to genetic deficiency or loss of function, leading to lysosomal storage disease‐like symptoms and neurodevelopmental impairmentDisruption may affect autophagy and cellular phospholipid metabolism
05

Biomarkers

Accumulation of lysophospholipids (e.g., lysophosphatidylcholine) in cells or tissues may serve as a biomarker for SPNS1 deficiency

Beyond the preview

Go deeper on Spinster homolog 1 (SPNS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spinster homolog 1 (SPNS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call